Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 11Gastrointestinal 6Other 4Lymphoid 4Dermatologic 4Genitourinary 3Thoracic 2Other hematologic neoplasm 2Plasma cell 1Other neoplasm 1Head & Neck 1CNS 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Docosahexaenoic Acids × Thoracic × Clear all
NCT00243867 2025-08-01

Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer

American Regent, Inc.

Phase 3 Completed
518 enrolled 16 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03936621 2019-05-07

Omega

British Columbia Cancer Agency

Phase 2 Unknown
42 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡